NCT02673476 is a Phase 2 clinical trial of ALS-008176 in Respiratory Syncytial Virus Infections, sponsored by Alios Biopharma Inc..

Who is sponsoring NCT02673476?

NCT02673476 is sponsored by Alios Biopharma Inc..

What drugs are being tested in NCT02673476?

Interventions in NCT02673476: ALS-008176, Placebo.

What condition does NCT02673476 study?

NCT02673476 studies Respiratory Syncytial Virus Infections.

Is NCT02673476 still recruiting?

NCT02673476 is currently completed. Last updated 4 February 2025.

Last reviewed 2025-02-04 · How we verify

NCT02673476

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

Completed Phase 2 Last updated 4 February 2025

What this trial tests

Phase 2 trial testing ALS-008176 in Respiratory Syncytial Virus Infections in 9 participants. Completed in 31 October 2016.

Timeline

29 February 2016

Primary endpoint
31 October 2016

31 October 2016

Quick facts

Lead sponsor	Alios Biopharma Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	9
Start date	29 February 2016
Primary completion	31 October 2016
Estimated completion	31 October 2016
Sites	21 locations across New Zealand, Taiwan, Australia, Singapore, United States

Drugs / interventions tested

ALS-008176 — full drug profile →
Placebo

Conditions studied

Respiratory Syncytial Virus Infections — all drugs for Respiratory Syncytial Virus Infections →

Sponsor

Alios Biopharma Inc. — full company profile →

Who can join

50 and older, any sex, with Respiratory Syncytial Virus Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being to see how effective and safe ALS-008176 is in treating adults in the hospital with a Respiratory Syncytial Virus-Related Illness.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.
Behzadi MA, Leyva-Grado VH. · · 2019 · cited 78× · PMID 31275265 · DOI 10.3389/fmicb.2019.01327
Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies.
Shang Z, Tan S, Ma D. · · 2021 · cited 74× · PMID 34671221 · DOI 10.7150/ijbs.64762

Verify or expand the search:

Other trials of ALS-008176

Trials testing the same drug.

NCT02833831 — Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants · Phase 1 · completed
NCT02231671 — A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176 · Phase 1 · completed
NCT02202356 — A Study of ALS-008176 in Infants Hospitalized With RSV · Phase 1 · completed
NCT01906164 — Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for Respiratory Syncytial Virus Infections

Currently open trials in the same condition.

NCT07214571 — A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of · Phase 2 · recruiting
NCT07220109 — A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 5 · Phase 3 · recruiting
NCT07239583 — Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus ) · recruiting
NCT07092865 — A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and th · Phase 2 · recruiting
NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting

Other Alios Biopharma Inc. trials

Trials by the same sponsor.

NCT03439488 — A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending · Phase 1 · completed
NCT03411421 — A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunte · Phase 1 · terminated
NCT03125213 — A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects · Phase 2 · withdrawn
NCT03285620 — A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Part · Phase 1 · completed
NCT03253471 — A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02673476 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alios Biopharma Inc.
Last refreshed: 4 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02673476.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing